Prot #ARV-110-mCRPC-101: A Phase 1/2, Open-label, Dose Escalation and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-110 in Patients with Metastatic Castration-resistant Prostate Cancer

Project: Research project

Project Details

StatusFinished
Effective start/end date7/31/20 → 7/31/23

Funding

  • Novella Clinical, LLC (Prot #ARV-110-mCRPC-101)
  • Arvinas Androgen Receptor, Inc. (Prot #ARV-110-mCRPC-101)